# US 5,700,487 A · Treatment of pulmonary inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,700,487 A
- Document ID: US5700487A
- Status: Granted
- Kind: A
- Application number: 08/610,271
- Filed: 1996-03-04
- Granted: 1997-12-23
- Earliest claimed: 1996-03-04
- Assignees: The Ohio State University
- Inventors: Nicholas Gerber; Glen Apseloff; Daniel I. Mullet
- Web page: https://patentgrep.com/patent/US5700487A

## CPC

- A61K 33/24: Heavy metals; Compounds thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of treating pulmonary inflammation in mammals, comprising administering an effective amount of a pharmaceutically acceptable gallium compound and wherein said gallium is elected from the group consisting of gallium nitrate, gallium citrate, gallium chloride, gallium carbonate, gallium acetate, gallium tartrate, gallium oxalate, gallium oxide, gallium arsenide and hydrated gallium oxide.

## Claims

### Claim 1

A method of treating pulmonary inflammation in mammals, comprising administering an effective amount of a pharmaceutically acceptable gallium compound selected from the group consisting of gallium nitrate, gallium citrate, gallium chloride, gallium carbonate, gallium acetate, gallium tartrate, gallium oxalate, gallium oxide, gallium arsenide, and hydrated gallium oxide.

### Claim 2 (depends on 1)

The method of claim 1 wherein said gallium compound is gallium nitrate.

### Claim 3 (depends on 1)

The method of claim 1 wherein said gallium compound is administered orally, intravenously, subcutaneously, intramuscularly, or through inhalation.

### Claim 4 (depends on 1)

The method of claim 1 wherein said gallium compound is administered prophylactically prior to the onset of said pulmonary inflammation.

### Claim 5 (depends on 1)

The method of claim 1 wherein said gallium compound is administered after the onset of said pulmonary inflammation.

### Claim 6 (depends on 1)

The method of claim 1 wherein said mammal is a human.

### Claim 7 (depends on 1)

The method of claim 1 wherein said pulmonary inflammation is associated with the disease asthma.